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Predictors of Survival for Patients with 
Non-small Cell Lung Cancer and Synchronous 
Brain Metastases with FDG-PET/CT Staging
Purpose
The clinical course of patients diagnosed with non-small cell lung 
cancer (NSCLC) with brain metastases (BM) at presentation is 
variable. Here we seek to identify predictors of survival in patients 
staged with FDG-PET/CT.
Method and Materials
We identified patients who were diagnosed with NSCLC with BM at 
presentation in the years 2007 or 2008 and underwent staging FDG-
PET/CT. Using a gradient-based semi-automatic contouring tool, 
hypermetabolic lesions were contoured on each patient’s PET scan. 
Maximum SUV, number of hypermetabolic lesions (NHL), total 
metabolic tumor volume (MTV), and various clinical factors were 
evaluated as predictors of overall survival.
Results
Twenty-five consecutive patients with NSCLC and BM at presentation 
were identified. Of those, 15 patients (60%) were alive 1 year after 
diagnosis, and 10 patients (40%) are still alive with median follow-up 
of 26.4 months (range: 16.2-33.9). Patients alive at 1 year were 
younger at diagnosis (mean 53.2 v. 63.1 years, p=0.01), had lower 
rate of extracranial metastases (7% v. 70%, p<0.01), and had lower 
MTV (41.8 v. 115.7 cc, p=0.02) than other patients. Gender, presence 
of multiple BM, maximum SUV, and NHL were not significantly 
related to survival at 1-year. A multivariate Cox proportional hazards 
model demonstrated that increasing age and presence of extracranial 
metastases were significantly associated with decreased survival. Of 
patients younger than 65 without extracranial metastases at diagnosis, 
12 out of 14 (86%) were alive at 1 year.
Conclusion
A subset of patients diagnosed with non-small cell lung cancer 
with brain metastases can be expected to have a good prognosis. 
Further study is required to determine the prognostic significance 
of quantitative FDG-PET/CT findings.
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